Abstract
Steady-state plasma imipramine levels were measured in 68 hospitalized children. Interindividual variability (imipramine 12-fold; desipramine 72-fold; 2 hydroxyimipramine 33-fold; 2 hydroxydesipramine 3-fold) was not correlated with clinical or demographic variables. However, intraindividual levels were reproducible and were linearly correlated with dose (r = 0.76; p < 0.005). Clinicians, by using plasma level monitoring, can rationally adjust dosages so that all patients will be in the optimum range, ensuring an adequate trial while avoiding supratherapeutic levels associated with cognitive toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
